Topotecan

Catalog No.S9321

For research use only.

Topotecan is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.

Topotecan Chemical Structure

CAS No. 123948-87-8

Selleck's Topotecan has been cited by 21 publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Other Topoisomerase Products

Biological Activity

Description Topotecan is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.
Targets
Topo I [1]
In vitro

Topotecan exhibits inhibition of outgrowth of the highly invasive and migratory leader cells (LC) population, however, topotecan enrichs the LC subset 20% above the untreated control level.<sup><a class="sref"href="#s_ref">[2]</a></sup>

In vivo

Topotecan (TPT), at least in part by inhibiting expression of Fli-1, significantly ameliorates lupus nephritis in NZBWF1 mice as effectively or better than cyclophosphamide (CYC).<sup><a class="sref"href="#s_ref">[3]</a></sup>

Protocol (from reference)

Cell Research:

<sup><a class="sref"href="#s_ref">[2]</a></sup>

  • Cell lines: LC-T2A-GFP lines
  • Concentrations: 1 μM
  • Incubation Time: 72 h
  • Method:

    LC-T2A-GFP lines are seeded at 1200 cells per well of a 384-well plate, adhered overnight, and treated with chemotherapeutics olaparib, rucaparib, paclitaxel, topotecan, carboplatin, cyclophosphamide, cisplatin, and doxorubicin at empirically determined clinically relevant doses (1 μM). Cells are maintained at 37 ℃ with 5% CO<sub>2</sub> in treatment for 72 h. Four focal areas per replicate well were imaged using 4X magnification on a bright field.

Animal Research:

<sup><a class="sref"href="#s_ref">[3]</a></sup>

  • Animal Models: NZBWF1 female mice
  • Dosages: 0.03 mg/kg, 0.1 mg/kg, 0.3mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 421.45
Formula

C23H23N3O5

CAS No. 123948-87-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04455139 Recruiting Drug: Topotecan|Drug: Melphalan Eye Cancer Retinoblastoma Prof. Beck Popovic Maja|University of Lausanne Hospitals November 15 2021 Phase 2
NCT05083000 Recruiting Drug: Topotecan COVID-19 Respiratory Infection National University Hospital Singapore|Christian Medical College Vellore India August 16 2021 Phase 1
NCT04156347 Recruiting Drug: Episcleral Topotecan Retinoblastoma Targeted Therapy Technologies LLC June 16 2021 Phase 1
NCT04428879 Recruiting Drug: Topotecan Episcleral Plaque Retinoblastoma The Hospital for Sick Children June 16 2020 Phase 1
NCT03927274 Recruiting Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute June 20 2019 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Topotecan | Topotecan supplier | purchase Topotecan | Topotecan cost | Topotecan manufacturer | order Topotecan | Topotecan distributor